- Home
- PAVM vs HOWL Comparison
PAVM vs HOWL Comparison
Compare PAVM & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PAVM | HOWL |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.1M | 46.7M |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PAVM | HOWL |
|---|---|---|
| Price | $2.11 | $0.97 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $36.50 | N/A |
| AVG Volume (30 Days) | 17.6K | ★ 395.6K |
| Earning Date | 11-12-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.40 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,000,000.00 | N/A |
| Revenue This Year | $132.39 | N/A |
| Revenue Next Year | $263.64 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 20.00 | N/A |
| 52 Week Low | $0.21 | $0.27 |
| 52 Week High | $43.99 | $1.33 |
Technical Indicators
Market Signals| Indicator | PAVM | HOWL |
|---|---|---|
| Relative Strength Index (RSI) | 28.25 | 49.74 |
| Support Level | $1.84 | $0.88 |
| Resistance Level | $6.56 | $0.99 |
| Average True Range (ATR) | 0.23 | 0.06 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 16.49 | 18.53 |
Price Performance
Historical ComparisonAbout PAVM PAVmed Inc.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, EsoCheck, and the Veris Cancer Care Platform.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.